期刊文献+

TRAIL及其受体DR4、DcR1在大肠癌及癌旁组织中的表达 被引量:4

Expression and Significance of TRAIL and Its Receptors DR4,DcR1 in Colorectal Carcinoma and The Surrounding Tissues
下载PDF
导出
摘要 目的研究人肿瘤坏死因子相关凋亡诱导配体(TNF-related apoptosis inducing ligand,TRAIL)及其受体DR4、DcR1在大肠癌和癌旁组织中的表达及意义。方法采用免疫组化SP法检测42例大肠癌及其癌旁5cm组织、25例正常大肠粘膜组织中TRAIL及其受体DR4、DcR1表达水平。结果TRAIL及DR4在大肠癌、癌旁组织及正常大肠粘膜组织中的表达呈递增趋势,而DcR1的表达则与之相反(P<0.05);TRAIL和DR4在中、低分化癌中的表达明显低于高分化癌中的表达,而DcR1的表达则与之相反(P<0.01);TRAIL、DR4、DcR1的表达与肿瘤的病理类型、Duke′s分期及淋巴结转移与否等因素无关(P>0.05)。结论TRAIL、DR4、DcR1可能与大肠癌的发生、发展密切相关;DR4可能在TRAIL诱导的凋亡通路中发挥一定作用,而DcR1的表达与否一定程度上决定了TRAIL能否发挥其生物效应。 Objective To study the expression and significance of TRAIL(TNF-related apoptosis- inducing ligand) DR4 and DcR1 in colorectal carcinoma and the surrounding tissues. Methods SP immunohistochemical technique was used to examine the expression of TRAIL and its receptors DR4,DcR1 in 42 cases of colorectal carcinoma and the surrounding tissues of 5cm distance and 25 cases of normal colorectal mucosa. Results The expression of TRAIL and DR4 was increased from colorectal carcinoma, surrounding tissues to normal colorectal mucosa, while DcR1 was opposite(P〈0. 05). The expression of TRAIL and DR4 was lower in moderate and poor differentiation degree than those in high differentiation degree, while DcR1 was opposite(P〈0. 01). There were no significant differences in the histology type, Dukes stages and lymph node metastasis or not of the expression of TRAIL, DR4 and DcR1(P〉0. 05). Conclusion TRAIL, DR4 and DcR1 may be closely correlated to the occurrence and the development of colorectal carcinoma. DR4 may play a certain role in the pathway of apoptosis induced by TRAIL. The effect of TRAIL may be partly determined by the expression of DcR1.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2006年第1期23-25,F0003,共4页 Cancer Research on Prevention and Treatment
基金 河北省科技攻关基金资助项目(2004014)
关键词 TRAIL DR4 DCR1 结直肠肿瘤 免疫组织化学 TRAIL DR4 DcR1 Colorectal neoplasm Irnmunohistochemistry
  • 相关文献

参考文献6

  • 1Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer[J].Mol Cells. 2003,15(3) :283-293.
  • 2Liu XS, Zhu Y, Han WN, et al. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1 and DcR2[J]. Hybrid hybridomics. 2003,22(2):121-123.
  • 3Krieg A, Krieg T,Wenzel M, et al. TRAIL-beta and TRAIL-gama:two novel splice variants of the human TNF-related apoptosis inducing ligand (TRAIL) without apoptosis potential[J]. Br J Cancer. 2003,88(6) :918-927.
  • 4Takeda K, Yarnaguchi N, Akiba H, et al. Induction of Tumorspecific T Cell Immunity by Anti-DR5 Antibody Therapy[J]. The Journal of Experimental Medidne. 2004,199(4): 437-448.
  • 5Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes [J].Cancer Res,2000,60(3) :553-559.
  • 6Chawla-Sarkar M, Bae SI, Reu FJ, et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo-2L/TRAIL- induced apoptosis[J]. Cell Death Differ, 2004,11 (8) :915-923.

同被引文献44

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部